What does Keros Therapeutics, Inc. do?

Jun 22 2025 06:57 PM IST
share
Share Via
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for hematological and musculoskeletal disorders. As of March 2025, it reported net sales of $211 million and a market cap of $546.68 million.
Overview:
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, operating within the Pharmaceuticals & Biotechnology industry and categorized as a small-cap company.

Financial Snapshot:
Most recent Net Sales: 211 Million (Quarterly Results - Mar 2025)
Most recent Net Profit: 148 Million (Quarterly Results - Mar 2025)
Market-cap: USD 546.68 Million (Small Cap)

Key Metrics:
P/E: 145.00
Dividend Yield: 0.00%
Debt Equity: -0.99
Return on Equity: 0.58%
Price to Book: 0.75

Contact Details:
Address: 99 Hayden Ave Ste 120 (Bld E, LEXINGTON MA : 02421
Tel: ['1 617 5138774', '1 646 3782936']
Website: https://www.kerostx.com/
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News